|

EIK1001 Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Pipeline

Phase 2/3: 2

Top Sponsors

  • Eikon Therapeutics2

Indications

  • Cancer2
  • Non Small Cell Lung Cancer (Squamous or Non Squamous)1
  • Stage 4 NSCLC1
  • Advanced Melanoma1
  • Lung Cancer1

Chandler, Arizona1 trial

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Ironwood Cancer & Research Centers

Phase 2/3

Mineola, New York1 trial

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

NYU Langone Hospital Long Island

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.